Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Above Two Hundred Day Moving Average - Time to Sell?

Key Points

• Spero Therapeutics stock has recently exceeded its 200-day moving average of $1.51, with current trading at $1.87.
• Analysts have a consensus rating of "Moderate Buy" for Spero Therapeutics, with a target price of $5.00 and a mix of Buy and Hold ratings among four analysts.
• The company reported a quarterly earnings beat, posting ($0.03) earnings per share against estimates of ($0.38), alongside revenues of $14.19 million.

Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report)'s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.51 and traded as high as $1.94. Spero Therapeutics shares last traded at $1.87, with a volume of 301,332 shares traded.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Spero Therapeutics to a "hold" rating in a report on Saturday, June 21st. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $5.00.

Spero Therapeutics Stock Performance

The stock has a market cap of $111.43 million, a price-to-earnings ratio of -2.02 and a beta of 1.39. The stock's 50-day simple moving average is $2.45 and its two-hundred day simple moving average is $1.52.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.03) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.35. The firm had revenue of $14.19 million during the quarter, compared to analyst estimates of $11.00 million. Spero Therapeutics had a negative net margin of 110.35% and a negative return on equity of 120.27%. As a group, research analysts predict that Spero Therapeutics, Inc. will post -1.2 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Invesco Ltd. acquired a new position in Spero Therapeutics in the second quarter worth about $43,000. XTX Topco Ltd acquired a new position in shares of Spero Therapeutics in the 4th quarter worth approximately $31,000. Quadrature Capital Ltd acquired a new position in shares of Spero Therapeutics in the 2nd quarter worth approximately $90,000. Axxcess Wealth Management LLC acquired a new position in shares of Spero Therapeutics in the 2nd quarter worth approximately $94,000. Finally, Capital Asset Advisory Services LLC acquired a new position in shares of Spero Therapeutics in the 2nd quarter worth approximately $94,000. Institutional investors and hedge funds own 25.60% of the company's stock.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.